OncoMatch/Clinical Trials/NCT05956821
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Is NCT05956821 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies SIACI of cetuximab and bevacizumab for glioblastoma multiforme.
Treatment: SIACI of cetuximab and bevacizumab — This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Lab requirements
Blood counts
absolute neutrophils ≥1000/mm3 and platelets ≥100,000/ mm3
Kidney function
creatinine <1.5x iunl
Liver function
bilirubin <1.5x iunl; ast or alt <2.5x iunl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Jackson Memorial Hospital · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify